Journal: Journal of Dental Sciences
Article Title: Fatostatin delayed lip sensory recovery after inferior alveolar nerve transection by inhibiting sterol regulatory element-binding protein 1
doi: 10.1016/j.jds.2025.04.024
Figure Lengend Snippet: Fatostatin inhibits axonal growth of primary trigeminal neurons in vitro . (A) Images of cultured primary neurons stained with NF200. The upper panels show the control group (left) and the fatostatin-treated group (right) at 20 × magnification. The lower panels show higher magnification (100 × ) of neurons in both groups. Scale bars in the upper panels indicate 100 μm, and in the lower panels, 20 μm. (B) Quantitative analysis of axonal length in the top 50 neurons, showing that fatostatin significantly reduced axonal growth compared to the control group. (C) Quantitative PCR analysis of key genes related to lipid metabolism and axonal regeneration, including SREBP1, FASN, ACLY, ATF3, and NGF. The results show that fatostatin treatment significantly reduced the expression levels of these genes, with SREBP1 and FASN showing the most prominent changes. (D) Western blot analysis of SREBP1, ACLY, and ATF3 protein expression levels, demonstrating that fatostatin treatment decreased SREBP1, ACLY, and ATF3 protein levels compared to control. GAPDH was used as the loading control. ∗∗∗, P < 0.001, ∗∗∗∗, P < 0.0001. SREBP1, sterol regulatory element-binding protein 1; FASN, fatty acid synthase; ACLY, ATP citrate lyase; ATF3, activating transcription factor 3; NGF, nerve growth factor.
Article Snippet: The used primary antibodies included SREBP1 (sc-13551, Santa Cruz, Dallas, TX, USA), ACLY (sc-517267, Santa Cruz), ATF3 (18665, Cell Signaling Technology, Boston, MA, USA), GAPDH (GB15002, Servicebio, Wuhan, China) After washing in TBST, membranes were incubated with the secondary antibody (ZSGB-BIO, Beijing, China), washed again in TBST, and visualized.
Techniques: In Vitro, Cell Culture, Staining, Control, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Binding Assay